Mindshift, il Consensus Europeo sull'Alzheimer firmato a Roma

In Europe, an estimated 9 million people have dementia, a number expected to exceed 14 million by 2050. In Italy, there are over one million, approximately 60% of whom have Alzheimer's disease, significantly impacting families, caregivers, and the sustainability of the welfare system. Yet, despite scientific advances in recent years, from new blood biomarkers to the first therapies capable of targeting the biological mechanisms of the disease and slowing its progression, European healthcare systems struggle to translate these advances into accessible care for patients. Diagnosis often arrives late, innovative therapies struggle to reach those who need them, and disparities between countries and regions remain profound. To develop a coordinated European response to these challenges, twelve countries gathered in Rome as part of "MindShift — A Cross-Country Mission to Reshape Alzheimer's Care," a transnational initiative that brought together policymakers, clinicians, and patient representatives from Italy, Germany, France, the Netherlands, Spain, Poland, Austria, Estonia, Hungary, the Czech Republic, Sweden, and Bulgaria. At the end of the meeting, a European consensus was signed with shared priorities, aiming to align national policies and ensure that scientific advances translate into concrete healthcare rights for all patients. MindShift is supported by AIMA, Fondazione Roma, SIBIOC, SIF, and SIN, and with the unconditional support of Lilly, Biogen, Eisai, Fujirebio, GE Healthcare, Roche SpA, Roche Diagnostics SpA, and Siemens Healthineers. Mario Zappia, President of the Italian Society of Neurology (SIN), Marco Bozzali, President of SINdem, an independent association affiliated with SIN for dementia, and Beatrice Lorenzin, Group Leader of the Parliamentary Intergroup for Alzheimer's, spoke on Medikea TV during the event. Interviews by Celeste Ottaviani #alzheimer's #dementia #degenerativediseases #neurology #health #diagnosis #medicine